{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:32:43Z","timestamp":1791325963864,"version":"4.3.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rearrangements of the c-myc oncogene have been found in most plasmacytomas induced in mice and human myeloma cell lines (HMCLs) analyzed so far. However, neither induced mouse plasmacytomas nor HMCLs represent relevant models for human multiple myeloma (MM). To evaluate the incidence of c-mycrearrangements in human plasma cell dyscrasias, sets of probes were generated to allow direct assessment of c-myctranslocations on interphase plasma cells by using fluorescence in situ hybridization. After validation of these probes, a large cohort of patients with either newly diagnosed MM (n\u2009=\u2009529), relapsed MM (n\u2009=\u200958), primary plasma cell leukemia (PCL; n\u2009=\u200923), monoclonal gammopathy of undetermined significance (n\u2009=\u200965), or smoldering MM (n\u2009=\u200924) were analyzed. C-myc rearrangements were identified in 15% of patients with MM or primary PCL, independently of the stage of the disease (ie, diagnosis or relapse and MM or primary PCL). Analysis of the 2 main translocations observed on karyotyping, ie, t(8;14) and t(8;22), revealed that these specific translocations represented only 25% (23 of 91) of c-mycrearrangements. c-myc rearrangements were then correlated with several other patients' characteristics: illegitimateIgH recombinations, chromosome 13 deletions, and serum \u03b22-microglobulin levels. The only significant correlation was with a high \u03b22-microglobulin level (P\u2009=\u2009.002), although a trend for association with t(4;14) was observed (P\u2009=\u2009.08). Thus, c-myc rearrangement analysis in patients with MM revealed a strikingly lower incidence than that in HMCLs and plasmacytomas induced in mice, indicating that data obtained with these models cannot be directly extrapolated to human MM.<\/jats:p>","DOI":"10.1182\/blood.v98.10.3082","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"3082-3086","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":250,"title":["Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors"],"prefix":"10.1182","volume":"98","author":[{"given":"Herve\u0301","family":"Avet-Loiseau","sequence":"first","affiliation":[{"name":"From the Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Gerson","sequence":"additional","affiliation":[{"name":"From the Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Magrangeas","sequence":"additional","affiliation":[{"name":"From the Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ste\u0301phane","family":"Minvielle","sequence":"additional","affiliation":[{"name":"From the Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[{"name":"From the Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Re\u0301gis","family":"Bataille","sequence":"additional","affiliation":[{"name":"From the Hematology Laboratory, INSERM U463, and the Department of Clinical Hematology, University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021216524180600_B1","first-page":"227","article-title":"Mouse plasmacytoma: an experimental model of human multiple myeloma.","volume":"86","author":"Gado","year":"2001","journal-title":"Haematologica."},{"key":"2020021216524180600_B2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/carcin\/13.10.1681","article-title":"Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations.","volume":"13","author":"Potter","year":"1992","journal-title":"Carcinogenesis."},{"key":"2020021216524180600_B3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.89.1.232","article-title":"Generation of plasmacytomas with the chromosomal translocation t(12;15) in the interleukin 6 transgenic mice.","volume":"89","author":"Suematsu","year":"1992","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021216524180600_B4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/j.1460-2075.1990.tb08187.x","article-title":"An E\u03bc-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.","volume":"9","author":"Rosenbaum","year":"1990","journal-title":"EMBO J."},{"key":"2020021216524180600_B5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/excr.1995.1083","article-title":"The functional basis of c-myc and bcl2 complementation during multistep lymphomagenesis in vivo.","volume":"217","author":"Marin","year":"1995","journal-title":"Exp Cell Res."},{"key":"2020021216524180600_B6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/bjc.1990.51","article-title":"The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations.","volume":"61","author":"Radl","year":"1990","journal-title":"Br J Cancer."},{"key":"2020021216524180600_B7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.V71.2.453.453","article-title":"Plasma cell karyotype in multiple myeloma.","volume":"71","author":"Gould","year":"1988","journal-title":"Blood."},{"key":"2020021216524180600_B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-I","article-title":"Cytogenetic findings in 200 patients with multiple myeloma.","volume":"82","author":"Sawyer","year":"1995","journal-title":"Cancer Genet Cytogenet."},{"key":"2020021216524180600_B9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia."},{"key":"2020021216524180600_B10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021216524180600_B11","first-page":"5640","article-title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.","volume":"58","author":"Avet-Loiseau","year":"1998","journal-title":"Cancer Res."},{"key":"2020021216524180600_B12","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","article-title":"Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.","volume":"83","author":"Zhang","year":"1994","journal-title":"Blood."},{"key":"2020021216524180600_B13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood.V73.4.1020.1020","article-title":"The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation.","volume":"73","author":"Pegoraro","year":"1989","journal-title":"Blood."},{"key":"2020021216524180600_B14","first-page":"729","article-title":"Establishment and characterization of two human myeloma cell lines secreting \u03ba light chains.","volume":"3","author":"Eton","year":"1989","journal-title":"Leukemia."},{"key":"2020021216524180600_B15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijc.2910360217","article-title":"Two distinct human myeloma cell lines originating from one patient with myeloma.","volume":"36","author":"Katagiri","year":"1985","journal-title":"Int J Cancer."},{"key":"2020021216524180600_B16","first-page":"93","article-title":"Two new IgA1-\u03ba plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2.","volume":"90","author":"Jackson","year":"1989","journal-title":"Clin Exp Immunol."},{"key":"2020021216524180600_B17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2141.1990.tb02540.x","article-title":"A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14.","volume":"74","author":"Nacheva","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021216524180600_B18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3181\/00379727-125-32327","article-title":"Production of free light chains of immunoglobulin by a haematopoietic cell line derived from a patient with multiple myeloma.","volume":"125","author":"Matsuoka","year":"1967","journal-title":"Proc Soc Exp Biol Med."},{"key":"2020021216524180600_B19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00320467","article-title":"Correlation of chromosomal aberrations in a myeloma cell line with tumorigenicity in nude mice.","volume":"43","author":"Kirchner","year":"1981","journal-title":"Blut."},{"key":"2020021216524180600_B20","first-page":"477","article-title":"Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.","volume":"7","author":"Nilsson","year":"1970","journal-title":"Clin Exp Immunol."},{"key":"2020021216524180600_B21","first-page":"274","article-title":"Establishment of a CD4-positive plasmacytoma cell line (AMO1).","volume":"7","author":"Shimizu","year":"1993","journal-title":"Leukemia."},{"key":"2020021216524180600_B22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2141.1990.tb04352.x","article-title":"Characterization of a new IgG\u03bb myeloma plasma cell line (EJM): a further tool in the investigation of the biology of multiple myeloma.","volume":"75","author":"Hamilton","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021216524180600_B23","first-page":"5320","article-title":"Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications.","volume":"53","author":"Jelinek","year":"1993","journal-title":"Cancer Res."},{"key":"2020021216524180600_B24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/(SICI)1098-2264(199811)23:3<220::AID-GCC3>3.0.CO;2-3","article-title":"Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization.","volume":"23","author":"Rack","year":"1998","journal-title":"Genes Chromosomes Cancer."},{"key":"2020021216524180600_B25","first-page":"2691","article-title":"Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).","volume":"95","author":"Janssen","year":"2000","journal-title":"Blood."},{"key":"2020021216524180600_B26","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood."},{"key":"2020021216524180600_B27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/geno.2000.6321","article-title":"The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations.","volume":"69","author":"Krummel","year":"2000","journal-title":"Genomics."},{"key":"2020021216524180600_B28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V97.3.822","article-title":"Cytogenetic, interphase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: study of 40 cases at diagnosis.","volume":"97","author":"Avet-Loiseau","year":"2001","journal-title":"Blood."},{"key":"2020021216524180600_B29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2141.2001.02546.x","article-title":"Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma.","volume":"112","author":"Sawyer","year":"2001","journal-title":"Br J Haematol."},{"key":"2020021216524180600_B30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","article-title":"Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.","volume":"18","author":"Ko\u0308nigsberg","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021216524180600_B31","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood."},{"key":"2020021216524180600_B32","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum \u03b22-microglobulin produce a very powerful myeloma staging system for patients receiving high dose therapy.","volume":"97","author":"Facon","year":"2001","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/3082\/1678263\/h8220103082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/3082\/1678263\/h8220103082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:21:29Z","timestamp":1581546089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/10\/3082\/52990\/Rearrangements-of-the-cmyc-oncogene-are-present-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,15]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.10.3082","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,15]]}}}